Login
$OCUL
$6.01 +$0.00 (0.0%) After hours

$OCUL 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

09 Nov 2026 8-K: Results of Operations and Financial Condition

AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis

16 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph.D., Chief Strategy Officer of Ocular Therapeutix, Inc. (the “Company”), notified the Company of his resignation from the Company, effective October 16, 2026, to become the Chief Executive O...

03 Aug 2026 8-K: Results of Operations and Financial Condition

Ocular’s AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026

12 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

05 May 2026 8-K: Results of Operations and Financial Condition

Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R

27 Feb 2026 8-K: Regulation FD Disclosure

At 4:15 pm Eastern Time on February 27, 2026, Ocular Therapeutix, Inc. (the “Company”) will make available under the Investors section of its corporate website the slides to be presented by the Company at the 49th Macula Society Annual M...

05 Feb 2026 8-K: Results of Operations and Financial Condition

SOL-1 Phase 3 superiority trial results remain masked to date

23 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

Effective as of January 20, 2026, Donald Notman, Chief Financial Officer and Chief Operating Officer (principal financial officer and principal accounting officer) of Ocular Therapeutix, Inc. (the “Company”), is taking a temporary medica...

18 Dec 2025 8-K: Other Events

As the Company prepares for database lock for its SOL-1 Phase 3 clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of wet age-related macular degeneration, the Company is entering a quiet period beginning December 20, 20...

05 Dec 2025 8-K: Other Events

The U.S. Food and Drug Administration (“FDA”) has historically required two adequate and well-controlled clinical trials to demonstrate the safety and efficacy of ophthalmic product candidates, in particular for larger indications such a...

04 Nov 2025 8-K: Results of Operations and Financial Condition

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability

30 Sep 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Introductory. Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 37,909,018 shares of its common stock, par va...

30 Sep 2025 8-K: Other Events

On September 30, 2025, Ocular Therapeutix, Inc., or the Company, announced certain updates regarding its development programs for AXPAXLI (also known as OTX-TKI), the Company’s investigational, bioresorbable, intravitreal hydrogel incorp...

05 Aug 2025 8-K: Results of Operations and Financial Condition

Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD

11 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more

Ocular Therapeutix, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, does hereby certify as follows:

05 May 2025 8-K: Results of Operations and Financial Condition

AXPAXLI™ SOL trials for wet AMD progressing rapidly following recent updates to accelerate and enhance the registrational program

03 Mar 2025 8-K: Results of Operations and Financial Condition

Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 months to showcase expected best-in-class durability

14 Feb 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

14 Nov 2024 8-K: Results of Operations and Financial Condition

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support